A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
Ahmad T, Riello RJ, Inzucchi SE. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review 2021, 16: e11. PMID: 33897837, PMCID: PMC8054345, DOI: 10.15420/ecr.2020.01.r1.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsType 2 diabetesCardiovascular diseaseHigh-risk type 2 diabetes patientsGlucagon-like peptide-1 receptor agonistsMajor adverse cardiovascular eventsSpecific glucose-lowering agentsPeptide-1 receptor agonistsRecent clinical trial dataType 2 diabetes patientsAdverse cardiovascular eventsHeart failure hospitalizationGlucose-lowering agentsClinical trial dataAnti-diabetes drugsCardiovascular eventsCardiovascular outcomesDiabetes medicationsFailure hospitalizationCardiovascular riskHeart failurePharmacological treatmentSafe prescribingDiabetes patientsEffect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure
Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.Peer-Reviewed Original ResearchConceptsEnd-stage heart failureReduced ejection fractionHealth-related qualityPatient-reported health statusEffect of inotropesHeart failureHealth status domainsEjection fractionHealth statusFunctional statusPositive inotropesStatus domainsAvailable clinical trial dataMorbidity/mortalityPopulation of patientsPatient-centered outcomesHealth status outcomesClinical trial dataFunctional capacity changesQuantity of lifeWeb of ScienceInotrope therapyInotrope useCalcium sensitizerSurvival benefit